Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study ; volume:14 ; number:1 ; day:3 ; month:7 ; year:2024 ; pages:1-11 ; date:12.2024
Scientific reports ; 14, Heft 1 (3.7.2024), 1-11, 12.2024
- Urheber
-
Nabizadeh, Fardin
Seyedmirzaei, Homa
Karami, Shaghayegh
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-66211-w
- URN
-
urn:nbn:de:101:1-2409231213046.006891633027
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nabizadeh, Fardin
- Seyedmirzaei, Homa
- Karami, Shaghayegh
- SpringerLink (Online service)
Ähnliche Objekte (12)
Author Correction: Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
The longitudinal trajectory of CSF sTREM2: the alzheimer’s disease neuroimaging initiative
Neuroimaging Biomarkers for Alzheimer’s Disease
Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
TREM2 regulates innate immunity in Alzheimer’s disease
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Bile acid profile associated with CSF and PET biomarkers in Alzheimer’s disease
CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Author Correction: Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
The longitudinal trajectory of CSF sTREM2: the alzheimer’s disease neuroimaging initiative
Neuroimaging Biomarkers for Alzheimer’s Disease
Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
TREM2 regulates innate immunity in Alzheimer’s disease
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Bile acid profile associated with CSF and PET biomarkers in Alzheimer’s disease
CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Author Correction: Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
The longitudinal trajectory of CSF sTREM2: the alzheimer’s disease neuroimaging initiative
Neuroimaging Biomarkers for Alzheimer’s Disease
Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
TREM2 regulates innate immunity in Alzheimer’s disease
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Bile acid profile associated with CSF and PET biomarkers in Alzheimer’s disease
CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease